Literature DB >> 14980491

Genomic diversity of human papillomavirus-16, 18, 31, and 35 isolates in a Mexican population and relationship to European, African, and Native American variants.

Itzel E Calleja-Macias1, Mina Kalantari, John Huh, Rocio Ortiz-Lopez, Augusto Rojas-Martinez, Juan F Gonzalez-Guerrero, Anna-Lise Williamson, Björn Hagmar, Dorothy J Wiley, Luis Villarreal, Hans-Ulrich Bernard, Hugo A Barrera-Saldaña.   

Abstract

Cervical cancer, mainly caused by infection with human papillomaviruses (HPVs), is a major public health problem in Mexico. During a study of the prevalence of HPV types in northeastern Mexico, we identified, as expected from worldwide comparisons, HPV-16, 18, 31, and 35 as highly prevalent. It is well known that the genomes of HPV types differ geographically because of evolution linked to ethnic groups separated in prehistoric times. As HPV intra-type variation results in pathogenic differences, we analyzed genomic sequences of Mexican variants of these four HPV types. Among 112 HPV-16 samples, 14 contained European and 98 American Indian (AA) variants. This ratio is unexpected as people of European ethnicity predominate in this part of Mexico. Among 15 HPV-18 samples, 13 contained European and 2 African variants, the latter possibly due to migration of Africans to the Caribbean coast of Mexico. We constructed phylogenetic trees of HPV-31 and 35 variants, which have never been studied. Forty-six HPV-31 isolates from Mexico, Europe, Africa, and the United States (US) contained a total of 35 nucleotide exchanges in a 428-bp segment, with maximal distances between any two variants of 16 bp (3.7%), similar to those between HPV-16 variants. The HPV-31 variants formed two branches, one apparently the European, the other one an African branch. The European branch contained 13 of 29 Mexican isolates, the African branch 16 Mexican isolates. These may represent the HPV-31 variants of American Indians, as a 55% prevalence of African variants in Mexico seems incomprehensible. Twenty-seven HPV-35 samples from Mexico, Europe, Africa, and the US contained 11 mutations in a 893-bp segment with maximal distances between any two variants of only 5 mutations (0.6%), including a characteristic 16-bp insertion/deletion. These HPV-35 variants formed several phylogenetic clusters rather than two- or three-branched trees as HPV-16, 18, and 31. An HPV-35 variant typical for American Indians was not identifiable. Our research suggests type specific patterns of evolution and spread of HPV-16, 18, 31, and 35 both before and after the worldwide migrations of the last four centuries. The high prevalence of highly carcinogenic HPV-16 AA variants, and the extensive diversity of HPV-18, 31, and 35 variants with unknown pathogenic properties raise the possibility that HPV intra-type variation contributes to the high cervical cancer burden in Mexico.

Entities:  

Mesh:

Year:  2004        PMID: 14980491     DOI: 10.1016/j.virol.2003.11.009

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  29 in total

1.  Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage.

Authors:  Long Fu Xi; Mark Schiffman; Laura A Koutsky; Zhonghu He; Rachel L Winer; Ayaka Hulbert; Shu-Kuang Lee; Yang Ke; Nancy B Kiviat
Journal:  Int J Cancer       Date:  2012-07-11       Impact factor: 7.396

Review 2.  Human papillomavirus genome variants.

Authors:  Robert D Burk; Ariana Harari; Zigui Chen
Journal:  Virology       Date:  2013-08-31       Impact factor: 3.616

Review 3.  The viral etiology of AIDS-associated malignancies.

Authors:  Peter C Angeletti; Luwen Zhang; Charles Wood
Journal:  Adv Pharmacol       Date:  2008

4.  Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population.

Authors:  Rosemary E Zuna; William E Moore; Rebecca P Shanesmith; S Terence Dunn; Sophia S Wang; Mark Schiffman; Gregory L Blakey; Travis Teel
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

5.  HPV frequency in penile carcinoma of Mexican patients: important contribution of HPV16 European variant.

Authors:  Ricardo López-Romero; Candela Iglesias-Chiesa; Brenda Alatorre; Karla Vázquez; Patricia Piña-Sánchez; Isabel Alvarado; Minerva Lazos; Raúl Peralta; Beatriz González-Yebra; Anae Romero; Mauricio Salcedo
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

6.  Variant upstream regulatory region sequences differentially regulate human papillomavirus type 16 DNA replication throughout the viral life cycle.

Authors:  Walter G Hubert
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16.

Authors:  Itzel E Calleja-Macias; Luisa L Villa; Jose C Prado; Mina Kalantari; Bruce Allan; Anna-Lise Williamson; Lap-Ping Chung; Robert J Collins; Rosemary E Zuna; S Terence Dunn; Tang-Yuan Chu; Heather A Cubie; Kate Cuschieri; Magnus von Knebel-Doeberitz; Claudia R Martins; Gloria I Sanchez; F Xavier Bosch; Nubia Munoz; Hans-Ulrich Bernard
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

8.  Genotype distribution of human papillomavirus (HPV) and co-infections in cervical cytologic specimens from two outpatient gynecological clinics in a region of southeast Spain.

Authors:  Pablo Conesa-Zamora; Sebastián Ortiz-Reina; Joaquín Moya-Biosca; Asunción Doménech-Peris; Francisco Javier Orantes-Casado; Miguel Pérez-Guillermo; Marcos Egea-Cortines
Journal:  BMC Infect Dis       Date:  2009-08-10       Impact factor: 3.090

9.  Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45, and 97.

Authors:  Zigui Chen; Rob DeSalle; Mark Schiffman; Rolando Herrero; Robert D Burk
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

Review 10.  Human papillomaviruses: genetic basis of carcinogenicity.

Authors:  Robert D Burk; Zigui Chen; Koenraad Van Doorslaer
Journal:  Public Health Genomics       Date:  2009-08-11       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.